Drugs / ZE74-0282
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | 2025-12-17 | “An IND application has been submitted to support first-in-human clinical studies of ZE74-0282.” eileanther.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07529951 | May 2026 → Sep 2028 expected | acquired polycythemia vera, myelofibrosis | Eilean Therapeutics | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Eilean Therapeutics | Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development eileanther.com ↗ |
| 2025-11-06 | Eilean Therapeutics | Eilean Therapeutics to Present First-in-Class, Wild-Type–Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025 eileanther.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZE74-0282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07529951 ↗ |
| Route | Oral | “Powder for suspension (sachets), oral, QD” NCT07529951 ↗ |